{
    "root": "9f81d6c6-279f-4fb4-9020-ec20416947f1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rivastigmine Transdermal System",
    "value": "20250320",
    "ingredients": [
        {
            "name": "RIVASTIGMINE",
            "code": "PKI06M3IW0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8874"
        }
    ],
    "indications": {
        "text": "rivastigmine transdermal system acetylcholinesterase inhibitor indicated treatment : mild , moderate , severe dementia alzheimer 's type ( Alzheimer 's disease ) ( 1.1 ) mild-to-moderate dementia associated parkinson 's disease ( pd ) ( 1.2 )",
        "doid_entities": [
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "apply patch intact skin 24-hour period ; replace new patch every 24 hours . ( 2.1 , 2.4 ) initial dose : initiate treatment 4.6 mg/24 hours rivastigmine transdermal system . ( 2.1 ) dose titration ( 2.1 ) : minimum 4 weeks , tolerated , increase dose 9.5 mg/24 hours , minimum effective dose . following minimum additional 4 weeks , may increase maximum 13.3 mg/24 hours . mild-to-moderate alzheimer 's disease parkinson 's disease dementia : rivastigmine transdermal system 9.5 mg/24 hours 13.3 mg/24 hours daily . ( 2.1 ) severe alzheimer 's disease : rivastigmine transdermal system 13.3 mg/24 hours daily . ( 2.1 ) treatment interruption longer 3 days , retitrate starting 4.6 mg per 24 hours . ( 2.1 ) consider dose adjustments patients ( 2.2 ) : mild-to-moderate hepatic impairment ( 8.6 ) low ( less 50 kg ) body weight ( 8.7 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "dementia (DOID:1307)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1307"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivastigmine transdermal system : 9.5 mg/24 hours patch 10 cm\u00b2 contains 18 mg rivastigmine base vivo release rate 9.5 mg/24 hours . carton 30 - ndc : 63629-2066-1 single patch - ndc : 63629-2066-2 store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep rivastigmine transdermal system individual sealed pouch . pouch contains 1 patch . used systems folded , adhesive surfaces pressed together , discarded safely . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "rivastigmine transdermal system contraindicated patients : known hypersensitivity rivastigmine , carbamate derivatives , components formulation [ description ( 11 ) ] . previous history application site rivastigmine transdermal patch suggestive allergic contact dermatitis [ ( 5.3 ) ] . isolated cases generalized skin described postmarketing experience [ ( 6.2 ) ] .",
    "indications_original": "Rivastigmine Transdermal System is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer's type (AD) ( 1.1 ) Mild-to-moderate dementia associated with Parkinson's disease (PD) ( 1.2 )",
    "contraindications_original": "Apply patch on intact skin for a 24-hour period; replace with a new patch every 24 hours. ( 2.1 , 2.4 ) Initial Dose : Initiate treatment with 4.6 mg/24 hours Rivastigmine Transdermal System. ( 2.1 ) Dose Titration ( 2.1 ) : After a minimum of 4 weeks, if tolerated, increase dose to 9.5 mg/24 hours, which is the minimum effective dose. Following a minimum additional 4 weeks, may increase dosage to maximum dosage of 13.3 mg/24 hours. Mild-to-Moderate Alzheimer's Disease and Parkinson's Disease Dementia : Rivastigmine Transdermal System 9.5 mg/24 hours or 13.3 mg/24 hours once daily. ( 2.1 ) Severe Alzheimer's Disease : Rivastigmine Transdermal System 13.3 mg/24 hours once daily. ( 2.1 ) For treatment interruption longer than 3 days, retitrate dosage starting at 4.6 mg per 24 hours. ( 2.1 ) Consider dose adjustments in patients with ( 2.2 ): Mild-to-moderate hepatic impairment ( 8.6 ) Low (less than 50 kg) body weight ( 8.7 )",
    "warningsAndPrecautions_original": "Rivastigmine Transdermal System: 9.5 mg/24 hours\n                  Each patch of 10 cm\u00b2 contains 18 mg rivastigmine base with in vivo release rate of 9.5 mg/24 hours.\n                  \n                     Carton of 30 - NDC: 63629-2066-1\n                     Single Patch - NDC: 63629-2066-2\n                  \n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep Rivastigmine Transdermal System in the individual sealed pouch until use. Each pouch contains 1 patch. Used systems should be folded, with the adhesive surfaces pressed together, and discarded safely.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Rivastigmine Transdermal System is contraindicated in patients with:\n                  \n                     known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see Description (11)].\n                     previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see Warnings and Precautions (5.3)].\n                  \n                  Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Rivastigmine Transdermal System",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8874"
        }
    ]
}